Japan PCSK9 Rivalry Builds As Praluent Edges Closer To Market
This article was originally published in PharmAsia News
Sanofi's Praluent looks set to become the second PCSK9 inhibitor available in Japan following a new recommendation for approval, but can it hold its own against launched rival Repatha? Meanwhile, AstraZeneca’s Brilinta is facing a delay.
You may also be interested in...
While Sanofi’s Japanese pharma business is feeling the impact of generic competition to its former blockbuster top product, it is aiming to move back into growth through a string of planned launches over the next few years.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.